Figure 3.

TG in PPP of patients with NSTEMI treated with clopidogrel in the presence or absence of VLD rivaroxaban. (A) Representative tracings and (B) arithmetic means ± SEM (n = 20) of lag time, TTP, peak (thrombin), and velocity of TG in PPP of patients with NSTEMI before (baseline) and after medication with clopidogrel + ASA at d1 in the absence (DMSO) or presence of 40 ng/mL rivaroxaban (in vitro) as well as following medication with clopidogrel + ASA and 2.5 mg rivaroxaban twice daily at d2 (in vivo). ***P < .001 indicates statistically significant differences from solvent control at the indicated time point. ##P < .01 and ###P < .001 indicate significant differences from baseline.